Sep 04, 2018
BiondVax to Present at Influenza 2018 Oxford Conference
Aug 22, 2018
BiondVax Announces Second Quarter 2018 Financial Results
Aug 20, 2018
BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
Aug 14, 2018
BiondVax Receives Second EUR6M Tranche Disbursement From the European Investment Bank (EIB)
Aug 08, 2018
First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
Jun 28, 2018
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
Jun 19, 2018
BiondVax Receives Its First EUR6M Tranche Disbursement From the European Investment Bank (EIB)
May 29, 2018
BiondVax Announces First Quarter 2018 Financial Results
Apr 30, 2018
BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
Apr 12, 2018
BiondVax to Present at Universal Influenza Vaccines Conference
Apr 11, 2018
BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States
Mar 13, 2018
BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
Feb 08, 2018
BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
Jan 02, 2018
BiondVax Universal Flu Vaccine Patent Granted in India
Dec 27, 2017
BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)
Dec 05, 2017
BiondVax's CEO Issues Letter to Shareholders
Nov 28, 2017
BiondVax Provides Third Quarter 2017 Financial Results and Update
Nov 20, 2017
BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine
Sep 18, 2017
BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option
Aug 31, 2017
BiondVax Provides Second Quarter 2017 Financial Results and Update